|
Originally published In Press as doi:10.1074/jbc.M108714200 on September 24, 2001
J. Biol. Chem., Vol. 276, Issue 47, 43887-43893, November 23, 2001
Regulation of Epithelial Sodium Channel Activity through a Region
of the Carboxyl Terminus of the -Subunit
EVIDENCE FOR INTRACELLULAR KINASE-MEDIATED REACTIONS*
Kenneth A.
Volk §,
Peter M.
Snyder ¶, and
John B.
Stokes §
From the Department of Internal Medicine and
¶ Department of Physiology and Biophysics, University of Iowa
College of Medicine and the § Veterans Affairs Medical
Center, Iowa City, Iowa 52246
Received for publication, September 10, 2001
 |
ABSTRACT |
The epithelial sodium channel (ENaC) is a
heteromultimer composed of three subunits, each having two
membrane-spanning domains with intracellular amino and carboxyl
termini. Several hormones and proteins regulate channel activity, but
the molecular nature of this regulation is unknown. We conducted
experiments to determine a possible new site within the carboxyl
terminus of the -subunit involved in enhanced channel activity
through endogenous kinases. When an -subunit that was truncated to
remove a PY motif was expressed in Xenopus oocytes with
wild type human - and -ENaC subunits, channel activity was
greatly enhanced. The removal of the entire intracellular carboxyl
terminus of the -subunit eliminated this enhanced basal activity.
Using several point mutations, we localized this site to two amino acid
residues (Pro595-Gly596) near the second
membrane-spanning domain. The nonspecific kinase inhibitor
staurosporine inhibits basal channel activity of wild type ENaC but was
ineffective in inhibiting channels mutated at this site. The major
effect of these mutations was not on channel kinetics but was largely,
if not entirely, on the number of active channels on the cell surface.
This region is potentially important in effecting kinase-mediated
increases in ENaC activity.
 |
INTRODUCTION |
The epithelial sodium channel
(ENaC)1 (1) in its fully
functional state is composed of three homologous subunits ( , , and ), which permit the entry of sodium across the apical membrane of the renal collecting duct, distal colon, lung, and other epithelial cells (1-3). ENaC plays a central role in sodium homeostasis and blood
pressure control. Activating mutations, such as truncations of the
intracellular carboxyl-terminal regions of -hENaC and -hENaC,
produce Liddle's syndrome, an autosomal dominant form of hypertension
(4-6). Inactivating mutations produce pseudohypoaldosteronism, a
disorder characterized by hypotension (7, 8).
Regulation of ENaC activity is of critical importance not only in
sodium balance and blood pressure regulation but also in regulating the
composition of airway fluid, sweat, and saliva (1, 3, 9). Considerable
effort has been directed at determining the humoral factors that can
influence ENaC activity, but relatively little is known about the
molecular events involved. It is well established that agents that
increase adenylate cyclase activity and cAMP can alter ENaC activity
acutely (10, 11). Activation of protein kinase C can also influence
ENaC activity (12, 13). However, the effects of activating these second
messenger systems are cell-specific (14, 15), and not all epithelial
cells expressing ENaC respond to these agents (16-18).
The topology of each of the ENaC subunits includes two
membrane-spanning domains, a large extracellular loop, and
intracellular amino and carboxyl termini (19-21). Evidence is
accumulating that ENaC activity may be mediated in part through these
intracellular regions. Mutations in the NH2 terminus of
ENaC can severely reduce function (22, 23). More attention has been
directed at the carboxyl termini, since patients with Liddle's
syndrome have mutations in this region of the - and -subunits (4,
24-29). The mutations that produce this syndrome disrupt the PY motif
(PPPXYXXL), a region responsible for binding
proteins with a WW domain (30). The protein Nedd4 has been strongly
implicated in binding to this region (31-34), and defects in the PY
motif cause more ENaC to reside in the membrane (6, 32, 33, 35, 36). To
date, there is little information about other proteins that might
interact with intracellular domains of ENaC subunits; nor is there much information about other intracellular regions that might play a role in
regulating ENaC function.
There is suggestive evidence that regions of the carboxyl termini other
than the PY motif are involved in regulating ENaC activity. Snyder
et al. (6) showed that mutating the tyrosine residue in the
PY motif of the -subunit (to alanine) increases the ENaC current to
the same extent as comparable mutations in the - and -subunits.
Truncation of the entire carboxyl termini of the - or -subunits
also produces a large increase in current. In contrast, truncation of
the carboxyl terminus of the -subunit does not increase ENaC current
(6, 37). Schild et al. (5) have also reported a smaller
response to truncating the -subunit compared with the - and
-subunits. These results suggest that the carboxyl terminus of the
-subunit may possess a domain(s) capable of regulating ENaC function
in a direction opposite to that of the PY motif. Perhaps this regional
functional diversity could explain why no patients with Liddle's
syndrome have been described with truncations or mutations in the
carboxyl terminus of the -subunit (2).
As we began to examine the role of the carboxyl-terminal regions
in greater detail, we found that the kinase inhibitor staurosporine strongly inhibited wild-type hENaC currents heterologously expressed in
Xenopus oocytes. Truncation of the carboxyl terminus of - or -hENaC, when expressed with the wild type partner subunits, did not alter the response to staurosporine. However, when the carboxyl
terminus of -hENaC was truncated, the inhibitory effect of
staurosporine was eliminated (37).
These results, taken together, prompted us to hypothesize that there is
a region within the carboxyl terminus of the -subunit that enhances
sodium current. Furthermore, we postulated that endogenous kinases
exist in Xenopus oocytes (and in mammalian epithelial cells)
that enhance the activity of ENaC. These kinases could act, directly or
indirectly, via a region in the intracellular carboxyl terminus of the
-subunit that is physically separate from the PY motif. The
following report provides evidence that this hypothesis is correct.
 |
MATERIALS AND METHODS |
The hENaC expression and current recordings have been described
previously (6, 32, 37). The coding regions of the -, -, and
-hENaC subunits were cloned into the PGEMHE plasmid and expressed
using cRNA injections after in vitro transcription with the
mMessage mMachine kit (Ambion). Xenopus laevis (Nasco)
oocytes were isolated as described previously (6, 32, 37). Briefly, oocytes were defolliculated with collagenase and stored in frog Ringer
solution consisting of 115 mM NaCl, 2.5 mM KCl,
1.8 mM CaCl2, 10 mM HEPES, 5 mM sodium pyruvate, and 100 µg/ml gentamicin. Each oocyte
was injected with 0.1-1 ng of cRNA for each hENaC subunit carried in
50 nl of nuclease-free water. Currents were recorded in frog Ringer
solution 48 h after injection. Whole cell currents were recorded
using an OC-725C oocyte voltage clamp (Warner Instruments). Single
channel currents were recorded in the cell-attached mode at room
temperature with 110 mM LiCl in the pipette and frog Ringer
solution in the bath. Single channel currents were recorded using an
Axopatch 2B (Axon Instruments). The pClamp software suite (Axon
Instruments) was used for coordinating voltage clamp amplifier command
potentials, current acquisition, and data analysis. Statistical procedures were applied with SigmaStat software (SPSS Science) using
analysis of variance and subsequent paired analysis as appropriate. Values are mean ± S.E.
In an effort to improve oocyte viability, some preparations were
incubated in frog Ringer solution supplemented with 10 µM amiloride after injection of RNA; amiloride was removed just before each current recording. The presence of amiloride in the incubation medium did not have any apparent effects on the qualitative
relationships between wild type and experimental groups. Since not all
groups could be evaluated on the same batch of oocytes and the control amiloride-sensitive currents varied substantially between batches, we
normalized all whole cell current magnitudes to the wild type controls
of each day. We evaluated the mutations that produced significant
changes in current in multiple batches with control oocytes having
different magnitudes of current. This approach permitted us to test a
range of basal currents for effects of stimulatory and inhibitory
mutations. All reported currents are those that demonstrated inhibition
by 25 µM amiloride.
Truncation mutations were constructed using the Exsite PCR-based
site-directed mutagenesis kit (Stratagene), and the point mutations
were constructed using the QuikChange site-directed mutagenesis kit
(Stratagene). For both strategies, since the entire hENaC coding region
was amplified by PCR (not just the mutated sequence), we sequenced the
mutated region to ensure the correct sequence had been changed. We
controlled for possible PCR errors in other regions by producing
another clone of the intended mutant with a separate PCR and verifying
the functional difference where there was one.
A cDNA clone of human SGK1 was generated using a nested PCR
strategy on total RNA from human renal papilla. The initial PCR primer
pair was ACGTCTTTCTGTCTCCCCG (positions 16-34 based on the numbering
in GenBankTM accession number Y100032) and
GGCTCCACCAAAAGGCTAAC (positions 1392-1411). The second round of
amplification was performed with a primer pair internal to the first
pair, ATGACGGTGAAAACTGAGGC (positions 43-62) and AAACCAAGCCCTAACAGGGT
(positions 1339-1358). The resulting amplicon, which included the full
coding region, was cloned using the PCR-Script Amp cloning kit
(Stratagene) and sequenced completely. Human SGK was subsequently
subcloned into the PGEMHE plasmid for in vitro transcription
of cRNA. The amount of cRNA injected for human SGK was 2 ng/oocyte,
which was double the amount of each hENaC subunit injected in these experiments.
Staurosporine was purchased from Biomol, and all other chemicals were
purchased from Sigma.
 |
RESULTS |
We hypothesized that there was a region in the intracellular
carboxyl terminus of -hENaC that permitted a high level of channel activity when all three wild type subunits were expressed. We therefore
sought to determine a specific region that, when mutated, would display
a reduction in endogenous channel activity. Fig. 1 shows the numbered positions of some
key amino acid residues and their positions relative to the predicted
second transmembrane domain (M2) and the PY motif.

View larger version (12K):
[in this window]
[in a new window]
|
Fig. 1.
Amino acid sequence of the carboxyl terminus
of -hENaC. The region marked
M2 is the final 5 amino acids of the predicted second
transmembrane domain. The PY motif is in boldface
type and marked for reference to the location of the
mutations (arrows) described here.
|
|
Mutations Influencing Endogenous ENaC Function--
We first
evaluated the S627X (n = 43) and S594X
(n = 18) truncations. The S627X truncation removes the
PY motif and all amino acids downstream but leaves most of the region
between M2 and the PY motif intact. This mutation should cause the
current to increase, because removing the PY motif would eliminate the
inhibitory region. Such a mutation would disrupt binding to Nedd4 and
increase surface expression of ENaC (6, 31, 32). Fig.
2 shows that this truncation indeed
increased current 4.5-fold. Next, we tested the S594X truncation, which
removes nearly the entire carboxyl terminus downstream of M2. This
mutant produced currents that were not significantly different from
wild type control currents. This result is consistent with the previous
report (6) and suggests that there is a region between amino acids
Ser594 and Ser627 that enhances ENaC
current.

View larger version (21K):
[in this window]
[in a new window]
|
Fig. 2.
Identification of a positive regulatory
region in the carboxyl terminus of
-hENaC. Whole cell amiloride-sensitive
currents were recorded from oocytes expressing wild-type and mutant
-hENaC along with wild type - and -subunits. Currents were
normalized to the -hENaC wild type controls for each oocyte batch.
The diagrams on the left indicate the nature of the
-hENaC C-terminal mutation with reference to M2, position
Ser594, and the PY motif. The asterisks
represent a statistical difference (p < 0.05) from
wild type control. The number of oocytes in each group ranged from 7 to
43.
|
|
Next, we examined a series of point mutations in the
Ser594-Ala602 region. Substituting all three
residues, Ser594, Pro595, and
Gly596, with alanine (AAA594; n = 11)
resulted in markedly decreased currents (11.5% of wild type control
currents; Fig. 2). Two other consecutive triple alanine substitutions,
AAA597 (n = 9) and AAA600 (n = 7), did
not cause a reduction in current; in fact, AAA597 caused an increase in
current (Fig. 2). These results suggest that the Ser594,
Pro595, and Gly596 residues participate in
molecular events that increase ENaC function. The lack of a reduction
in current with the other AAA mutations demonstrates that the AAA594
effect is not a general property of AAA mutations in that region. We
hypothesized that the currents from the S594X mutant were not different
from control, because this truncation eliminated at least two
functional regions: one that caused a decrease in current (the PY
motif) and one that caused an increase in current (Ser594).
To test this hypothesis, we constructed a mutant (AAA594/S627X) that
eliminated both the stimulatory region and the inhibitory region. As
predicted, AAA594/S627X (n = 8) resulted in currents that were not different from either wild type controls or S594X mutants
(Fig. 2).
We asked which of the mutations in the AAA594 construct were critical
to the change in function. P595A (n = 24) or G596A
(n = 17) caused a significant reduction in current,
whereas S594A (n = 8) had no effect (Fig. 2),
indicating that the proline and glycine residues are critical for
normal function. The lack of effect of mutating the Ser594
residue suggests that even if this residue is directly phosphorylated by endogenous kinases, there is minimal effect on ENaC function.
Mutations Affecting Actions of Endogenous Kinases--
To
determine whether the positive regulatory region described in Fig. 2
was also the region involved in enhanced ENaC activity by endogenous
kinases (37), we tested the acute response of these mutants to 100 nM staurosporine (Fig. 3).
Truncations T646X (n = 4), S627X (n = 11), and S615X (n = 4) produced currents that were
similarly inhibited by staurosporine. In contrast, truncation S594X
(n = 12) produced currents that were not inhibited by
staurosporine. These results suggested that the region between
Ser594 and Ser615 was important in producing a
stimulatory effect that could be reduced by inhibiting an endogenous
kinase.

View larger version (24K):
[in this window]
[in a new window]
|
Fig. 3.
Identification of a staurosporine-sensitive
region in the carboxyl terminus of
-hENaC. Each bar represents the
fraction of inward ENaC current remaining after a 10-min exposure to
100 nM staurosporine (compared with wild type in the same
preparation). The diagrams on the left indicate the nature
of the mutation. The line at 1.0 represents no inhibition by
staurosporine. The asterisks represent a statistical
difference (p < 0.05) from wild type control. The
-hENaC mutants were expressed with wild type - and -hENaC. The
number of oocytes in each group ranged from 3 to 18 with at least six
oocytes in at least two batches for groups that had no response to
staurosporine.
|
|
We assessed the effect of staurosporine on point mutations identical to
those we tested for endogenous ENaC activity. ENaC currents in oocytes
expressing AAA594 (n = 8) were apparently insensitive
to staurosporine (Fig. 3). However, since these currents were
relatively small (<1 µA at 60 mV), we considered the possibility that we could have missed the inhibition. We therefore tested the
staurosporine sensitivity of the currents produced by the AAA594/S627X
mutation (n = 7), since these currents were similar to
those from wild type hENaC (Fig. 2). As shown in Fig. 3, these currents
were not inhibited by staurosporine and thus indicate that the residues
in positions 594-596 are important for the response to staurosporine.
Currents produced by either AAA597 (n = 12) or AAA600
(n = 3) were staurosporine-sensitive (Fig. 3). When we
tested the single amino acid substitution mutants S594A
(n = 12), P595A (n = 18), and G596A
(n = 10), we found that only P595A currents showed
substantial insensitivity to staurosporine.
Staurosporine is a nonspecific kinase inhibitor. Recently, SGK
has been shown to increase ENaC currents in oocytes (38, 39). We
therefore tested the hypothesis that this Ser594 region
might be important in mediating this SGK effect. An additional rationale is that Ser594 is a consensus serine for
phosphorylation by SGK (40, 41). However, as shown in Fig.
4A, co-expressing SGK
increased current by ~2-fold in both wild type ENaC and the S594X
mutation. These results make it unlikely that the inhibition of current
by staurosporine is the result of inhibiting an endogenous SGK-like
kinase.

View larger version (15K):
[in this window]
[in a new window]
|
Fig. 4.
SGK and staurosporine effects on currents
with other mutations in -hENaC.
A, human SGK was subcloned into the pGEMHE vector and
coexpressed with wild type ENaC or the S594X truncation of -hENaC.
The lack of the majority of the COOH terminus including the
Ser594 residue, a possible phosphorylation site for SGK,
did not alter SGK's ability to enhance current (n = 15 in each group; *, p < 0.02 compared with control).
B, the Ser590 site of -hENaC was mutated to
alanine (S590A) and coexpressed with wild type - and -hENaC. Wild
type hENaC and the mutant were incubated with 100 nM
staurosporine for 30-120 min. This mutation produced no change in
basal current or the effect of staurosporine (n = 34-39 in each group from six batches of oocytes; *, p < 0.05 compared with controls by analysis of variance and subsequent
Dunn's test for multiple comparisons).
|
|
The disruption of the Pro595-Gly596 locus might
perturb a binding site important for a kinase involved in
phosphorylating a nearby residue. Inspection of the neighboring
sequence reveals that Ser590 is a potential target for
several kinases. We therefore mutated this residue to alanine and
tested the effects of staurosporine in oocytes. There was no effect of
the mutation on basal current, and staurosporine had the same effect in
wild type and mutated hENaC currents (Fig. 4B).
We also tested the effects of another kinase inhibitor, chelerythrine
(10 µM), on wild-type and AAA594 mutants. This inhibitor is less potent than staurosporine in this assay (37), but is more
specific for protein kinase C. The effects on wild-type currents were
the same as before, ~50% reduction. However, as in the case of
staurosporine, chelerythrine had no effect on currents produced by the
AAA594 mutation (data not shown).
Single Channel Analysis of -hENaC Mutants--
These mutations
identify a specific region of -hENaC
(Pro595-Gly596) that appears to be required for
the normal expression of ENaC currents and staurosporine sensitivity.
We examined the mechanism by which this region affects hENaC function
using single channel current recordings. This analysis allows us to
assess whether the decrease in whole cell current produced by a
mutation is caused by a decrease in the single channel current
conductance (g) or the probability of a channel being open
(Po). We reasoned that the mutant AAA594 (which
caused a ~90% decrease in current) presented the best opportunity to
evaluate whether changes in these single channel properties could
explain the reduction in whole cell current.
Fig. 5A shows single channel
recordings from an oocyte expressing AAA594 channels. The current
amplitude for channel openings at 60 mV was ~1 pA. Since wild type
single channel currents have a similar magnitude (6, 32), this result
eliminates the possibility that the reduced whole cell current in this
mutant could be caused by a 90% decrease in g. The
individual Po values for 14 patches are shown in
Fig. 5B and demonstrate the high variability that we (6, 32)
and others (5) have previously reported. The mean value of 0.27 is not
appreciably different from our previously reported values under the
same conditions. These results make it extremely unlikely that changes
in g or Po can explain all of the
reduction in whole cell current produced by AAA594.

View larger version (12K):
[in this window]
[in a new window]
|
Fig. 5.
Single channels from AAA594 mutants
demonstrate typical wild type hENaC characteristics. A,
representative single channel activity recorded from a cell-attached
patch in an oocyte expressing AAA594 ENaC
channels. The holding voltage was 60 mV, and downward deflections are
channel openings. There were at least two channels in this patch.
B, Po values for each of 14 cell-attached patches studied are displayed on the left
half (Ind), and the average
Po value for these patches of 0.27 ± 0.06 is on the right.
|
|
The Number of hENaC Channels in the Membrane--
We directed our
efforts at determining whether the reduced hENaC current in the AAA594
mutants might have been due to a reduced number of channels in the
membrane. A mutation in the -hENaC subunit (S520K) when expressed
with wild type - and -subunits increases the
Po of all ENaC channels to >0.9 (42). We
expressed (S520K) in combination with wild type and mutant -ENaC,
reasoning that if all channels in the membrane had a
Po approaching 1.0, then any decrease in whole
cell current caused by a mutation in -hENaC must be caused by a
smaller number of functional channels in the membrane. First, we
determined the effect of (AAA594) on Po by
injecting equimolar (AAA594) and (S520K) with (wt) and
measured single channel currents. These channels (an example of which
is shown in Fig. 6A) were
characterized by a slightly lower value for g (slope
conductance = 6.5 picosiemens), long openings, and
uncharacteristically brief closures. The Po
values for a population of these channels are >0.9 (Fig.
6B) with the exception of one patch (of seven). In the one
patch with a Po of 0.5, there appeared to be two
channels, with the channel openings and closings being consistent
with one very high Po channel and one very low
Po channel.

View larger version (11K):
[in this window]
[in a new window]
|
Fig. 6.
Single
AAA594 S520K -ENaC
channels demonstrate high Po kinetic
characteristics. A, representative single channel
activity recorded from a cell-attached patch in an oocyte expressing
AAA594 S520K -ENaC channels. The holding
voltage was 60 mV, and downward deflections are channel openings.
There was apparently only one hENaC channel in this patch. The brief,
large amplitude spikes are probably the stretch-activated nonselective
cation channel, which is present in all oocyte membranes. B,
Po values for each of 14 cell-attached patches
studied are displayed on the left half, and the
average Po value for these patches of 0.27 ± 0.06 is on the right.
|
|
Having demonstrated that nearly all (AAA594), (S520K), and
(wt) channels have a Po approaching 1.0, we
measured whole cell currents for these and mutants
independently and combined. As shown in Fig.
7, the (AAA594) channel whole
cell currents were significantly diminished compared with control,
whereas the  (S520K) channel currents were increased ~5-fold
over the wild type channel. The double mutant channel currents were
both significantly larger than (AAA594) currents and smaller
than  (S520K) currents. These data strongly suggest that the
decreased whole cell current in the (AAA594) mutant results
primarily from a smaller number of functional channels in the
membrane.

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 7.
Coexpression of
(AAA594) with (S520K)
substantially decreases whole cell currents. Whole cell
amiloride-sensitive currents were recorded from oocytes expressing
combinations of AAA594 and S520K ENaC. The latter mutation causes
the Po to increase toward unity (Fig.
6B; Ref. 42). The number of oocytes in each group (from six
batches) is shown in parentheses. See "Results" for
interpretation.
|
|
 |
DISCUSSION |
The carboxyl-terminal region of -hENaC contains at least two
domains that can regulate the function of the heteromultimeric molecular complex. The PY motif acts as an inhibitory domain (31-33). We now show that the Pro595-Gly596 residues
provide the capability for enhanced activity. The requirement for an
intact Pro595 residue for both "normal" ENaC activity
and for the inhibition by staurosporine suggests that endogenous
kinases mediate certain events that ultimately increase ENaC activity
through interactions with this region. It seems likely that this
function is confined to the -subunit, since there is no similar
sequence in the - or -ENaC subunit, and truncation of the COOH
terminus of either - or -ENaC does not change the staurosporine
sensitivity (37).
It seems unlikely that the mutations in the amino acids 594-596
produce nonspecific changes causing inactivation of the channel. The
fact that the AAA594/S627X mutation produces the same magnitude of
current as wild type (Fig. 2) suggests that the AAA594 mutation does
not cause severe disruption to protein synthesis or irreversible channel dysfunction. The AAA mutations themselves do not seem to be
generally disabling, since these mutations in the 6 amino acid residues
immediately downstream have no inhibitory effect. The single amino acid
mutations P595A and G596A produce changes of a similar magnitude,
further suggesting specificity for this region. Finally, the fact that
mutations in this region prevent inhibition of the current by
staurosporine (Fig. 3) suggests that basal ENaC activity is mediated
via endogenous kinases that involve specific interactions with this region.
The nature of the presumed endogenous kinase activity in the
oocyte is not clear. Since inhibitors of several different classes of
kinases can effect at least a partial inhibition of hENaC currents (37), we presume that several may be acting in concert. Interestingly, the Pro595 region is probably not interacting exclusively
with the kinases that are most commonly associated with altering ENaC
activity. Although the effect of the protein kinase C inhibitor,
chelerythrine, was eliminated with the AAA594 mutation, this inhibitor
produces a less complete inhibition of current than does staurosporine (37). Inhibitors of cAMP have no effect on ENaC activity in oocytes
(37). The kinase activity is also unlikely to be SGK (Fig.
4A), since truncation of this region did not eliminate the ability of SGK to increase ENaC currents. This result is consistent with those reported by two other laboratories using different approaches (43, 44).
The precise nature of the Pro595 region that is responsible
for the effect of endogenous kinases remains unclear. There is no convincing evidence for in vivo phosphorylation of any
region of the -hENaC carboxyl terminus (45), although in
vitro phosphorylation has been reported (46). The lack of effect
of mutating Ser594 indicates that even if this residue is
phosphorylated, the functional effects on ENaC current are minimal.
Mutating Pro595 had the most dramatic effect both on basal
current and on the ability of staurosporine to reduce current (Figs. 2
and 3). From this perspective, we speculate that Pro595
imparts an important secondary conformation. When we model the secondary structure of this region using the plot (Fig.
8) of the Chou-Fasman secondary structure
prediction module of the GCG computer program (Pharmacopeia, Inc.), we
see that replacing the proline with an alanine is predicted to result
in the loss of a major turn. Not only is this immediate region
distorted by the P595A mutation, but the orientation of the remainder
of the carboxyl terminus is probably also altered. This effect raises
the possibility that the interactions disrupted by mutating
Pro595 may not be confined to the immediate region.
Although the truncation experiments (Figs. 2 and 3) reinforce the
likelihood that this region is quite important, there could be effects
on other sites resulting from a major alteration in secondary
structure. Evidently, the potential phosphorylation site
Ser590 is not involved (Fig. 4B).

View larger version (6K):
[in this window]
[in a new window]
|
Fig. 8.
P595A mutation causes significant structural
changes. The PeptideStructure program of GCG produced this
Chou-Fasman secondary structure prediction plot of the 20 amino acids
surrounding P595A (RRFRSRYWSPGRGGRGAQEV) in the carboxyl terminus of
-hENaC. The symbols represent areas of hydrophilicity.
The arrow points to position 595, where the proline
(A) is mutated to an alanine (B).
|
|
The P595A mutation reduced both basal current and the inhibition by
staurosporine. However, the G596A mutation had a pronounced reduction
of basal current but little or no difference in the staurosporine
effect. The reason for this apparent difference is not clear. It is
possible that measuring the fractional inhibition of current when the
starting value is low may not be quantitatively consistent.
Alternatively, the relationship between basal ENaC activity and
endogenous kinase activity may not be tightly linked via this region.
We have no data addressing this matter.
We can infer general molecular explanations for the importance of the
Pro595 region from the present data. It is possible that a
kinase interacts with this region and phosphorylates a nearby residue
(although apparently not Ser594 or Ser590). It
is also possible that a kinase interacts with this region but
phosphorylates a distant residue, perhaps on a distal portion of
-ENaC, a different ENaC subunit, or another associated protein. Alternatively, this site might interact with a protein that is phosphorylated by an endogenous kinase or a protein that interacts with
a phosphorylated protein. The idea that another region within the
carboxyl terminus of -ENaC is involved with regulating channel activity has recently been proposed by Copeland et al. (47). These investigators observed that a region between the
Pro595 locus and the PY motif is necessary to permit actin
to alter the gating characteristics of the homomeric channel studied in bilayers. Whether there is a functional connection between any of these
regions remains to be determined.
We surmise that the major mechanism by which mutations in the PG region
produce a change in current is by changing the number of functional
channels on the cell surface. This conclusion rests with the negative
evidence of a change in single channel properties (Fig. 4) and the
positive effect of a mutation that maintains the channel in a largely
open configuration (Fig. 5). While the data are adequate to make this
general conclusion, they are not sufficiently sensitive to eliminate
the possibility that this region does participate in some way in
modulating channel gating. This argument has been raised with mutations
that eliminate the PY motif on the - and -ENaC subunits (6, 35),
because changes in cell surface expression may not explain all of the
change in whole cell current. The wide variability of
Po and relatively slow kinetics exhibited by
wild type ENaC make detection of subtle changes rather difficult. In
addition, the reproducibility of chemical estimates of ENaC surface
expression makes these approaches somewhat
insensitive.2
In our view, the use of the (S520K) mutation to produce a channel
complex with a high Po (Fig. 6; Ref. 42)
increases the certainty with which we can conclude that there is a
change in surface expression. We emphasize that this technique
identifies functionally active channels and would not detect silent
channels residing in the membrane. In this regard, some investigators
have proposed that there are a large number of ENaC complexes on the cell surface that have a very low Po (35). The
resolution of these questions will require more sensitive and specific
techniques than those currently available.
The conclusion that a major effect of endogenous kinases acting via
this region influences surface expression is consistent with a growing
body of evidence suggesting that surface expression is a major
mechanism of ENaC regulation. There is solid evidence that increasing
SGK activity increases ENaC current by increasing surface expression in
oocytes (43). There is also good evidence that cAMP increases ENaC
current by increasing surface expression in mammalian epithelial cells
(11). In addition to the actions of kinases, structural factors can
produce changes in surface expression. Examples of such "structural
changes" include mutations causing Liddle's syndrome (6, 33, 35),
changes in syntaxin expression (48, 49), and alteration in Nedd4 (32,
33). Perhaps regulation of ENaC surface expression and function by kinase activity might be linked to the integrated actions of some or
all of these proteins.
 |
ACKNOWLEDGEMENTS |
We appreciate the technical assistance of
Nancy Wertz. Services were provided by the University of Iowa Diabetes
and Endocrinology Research Center.
 |
FOOTNOTES |
*
This work was supported in part by National Institutes of
Health (NIH) O'Brien Kidney Research Center Grant DK52617, NIH
Specialized Center of Research Grant HL55006, and a grant from the
Department of Veterans Affairs. The University of Iowa Diabetes and
Endocrinology Research Center was supported by NIH Grant
DK25295.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed: E300 GH, Dept. of
Internal Medicine, University of Iowa, Iowa City, IA 52246. Tel.:
319-356-4409; Fax: 319-356-2999; E-mail: john-stokes@uiowa.edu.
Published, JBC Papers in Press, September 24, 2001, DOI 10.1074/jbc.M108714200
2
K. A. Volk, P. M. Snyder, and J. B. Stokes, unpublished observations.
 |
ABBREVIATIONS |
The abbreviations used are:
ENaC, epithelial
sodium channel;
hENaC, human ENaC;
M2, second membrane-spanning domain;
AAA594, a mutation where the amino acid residue at position 594 and the
next two residues were mutated to alanine;
g, single channel
current conductance;
Po, probability of a
channel being open;
wt, wild type;
PCR, polymerase chain
reaction.
 |
REFERENCES |
| 1.
|
Garty, H.,
and Palmer, L. G.
(1997)
Physiological Rev.
77,
359-396[Abstract/Free Full Text]
|
| 2.
|
Stokes, J. B.
(1999)
Kidney Int.
56,
2318-2333[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Alverez de la Rosa, D.,
Canessa, C. M.,
Fyfe, G. K.,
and Zhang, P.
(2000)
Annu. Rev. Physiol.
62,
573-594[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Shimkets, R. A.,
Warnock, D. G.,
Bositis, C. M.,
Nelson-Williams, C.,
Hansson, J. H.,
Schambelan, M.,
Gill, J. R.,
Ulick, S.,
Milora, R. V.,
Findling, J. W.,
Canessa, C. M.,
Rossier, B. C.,
and Lifton, R. P.
(1994)
Cell
79,
407-414[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Schild, L.,
Canessa, C. M.,
Shimkets, R. A.,
Gautschi, I.,
Lifton, R. P.,
and Rossier, B. C.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
5699-5703[Abstract/Free Full Text]
|
| 6.
|
Snyder, P. M.,
Price, M. P.,
McDonald, F. J.,
Adams, C. M.,
Volk, K. A.,
Zeiher, B. G.,
Stokes, J. B.,
and Welsh, M. J.
(1995)
Cell
83,
969-978[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Chang, S. S.,
Grunder, S.,
Hanukoglu, A.,
Roaler, A.,
Mathew, P. M.,
Hanukoglu, I.,
Schild, L.,
Lu, Y.,
Shimkets, R. A.,
Nelson-Williams, C.,
Rossier, B. C.,
and Lifton, R. P.
(1996)
Nat. Genet.
12,
248-253[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
Gründer, S.,
Firsov, D.,
Chang, S. S.,
Jaeger, N. F.,
Gautschi, I.,
Schild, L.,
Lifton, R. P.,
and Rossier, B. C.
(1997)
EMBO J.
16,
899-907[CrossRef][Medline]
[Order article via Infotrieve]
|
| 9.
|
Barbry, P.,
and Hofman, P.
(1997)
Am. J. Physiol.
273,
G571-G585[Abstract/Free Full Text]
|
| 10.
|
Frindt, G.,
Silver, R. B.,
Windhager, E. E.,
and Palmer, L. G.
(1995)
Am. J. Physiol.
268,
F480-F489[Abstract/Free Full Text]
|
| 11.
|
Snyder, P. M.
(2000)
J. Clin. Invest.
105,
45-53[Medline]
[Order article via Infotrieve]
|
| 12.
|
Frindt, G.,
Palmer, L. G.,
and Windhager, E. E.
(1996)
Am. J. Physiol.
270,
F371-F376[Abstract/Free Full Text]
|
| 13.
|
Stockand, J. D.,
Bao, H.,
Schenck, J.,
Malik, B.,
Middleton, P.,
Schlanger, L. E.,
and Eaton, D. C.
(2000)
J. Biol. Chem.
275,
25760-25765[Abstract/Free Full Text]
|
| 14.
|
Chalfant, M. L.,
Civan, J. M.,
Peterson-Yantorno, K.,
DiBona, D. R.,
O'Brien, T. G.,
and Civan, M. M.
(1996)
J. Membr. Biol.
152,
207-215[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
Chen, L.,
Reif, M. C.,
Schafer, J. A.,
Corbitt, B. D.,
Parris, M. G.,
and Williams, S. K.
(1991)
Am. J. Physiol.
261,
F126-F136[Abstract/Free Full Text]
|
| 16.
|
Chalfant, M. L.,
Peterson-Yantorno, K.,
O'Brien, T. G.,
and Civan, M. M.
(1996)
Am. J. Physiol. Renal
271,
F861-F870[Abstract/Free Full Text]
|
| 17.
|
Nagy, E.,
Náray-Fejes-Tóth, A.,
and Fejes-Tóth, G.
(1994)
Am. J. Physiol.
267,
F831-F838[Abstract/Free Full Text]
|
| 18.
|
Husted, R. F.,
and Stokes, J. B.
(1996)
Am. J. Physiol.
271,
F433-F439[Abstract/Free Full Text]
|
| 19.
|
Snyder, P. M.,
McDonald, F. J.,
Stokes, J. B.,
and Welsh, M. J.
(1994)
J. Biol. Chem.
269,
24379-24383[Abstract/Free Full Text]
|
| 20.
|
Renard, S.,
Lingueglia, E.,
Voilley, N.,
Lazdunski, M.,
and Barbry, P.
(1994)
J. Biol. Chem.
269,
12981-12986[Abstract/Free Full Text]
|
| 21.
|
Canessa, C. M.,
Merillat, A.,
and Rossier, B. C.
(1994)
Am. J. Physiol.
267,
C1682-C1690[Abstract/Free Full Text]
|
| 22.
|
Grunder, S.,
Zagato, L.,
Yagil, C.,
Yagil, Y.,
Sassard, J.,
and Rossier, B. C.
(1997)
J. Hypertension
15,
173-179[CrossRef][Medline]
[Order article via Infotrieve]
|
| 23.
|
Chalfant, M. L.,
Denton, J. S.,
Langloh, A. L.,
Karlson, K. H.,
Loffing, J.,
Benos, D. J.,
and Stanton, B. A.
(1999)
J. Biol. Chem.
274,
32889-32896[Abstract/Free Full Text]
|
| 24.
|
Hansson, J. H.,
Nelson-Williams, C.,
Suzuki, H.,
Schild, L.,
Shimkets, R.,
Lu, Y.,
Canessa, C.,
Iwasaki, T.,
Rossier, B.,
and Lifton, R. P.
(1995)
Nat. Genet.
11,
76-82[CrossRef][Medline]
[Order article via Infotrieve]
|
| 25.
|
Hasson, J. H.,
Schild, L.,
Lu, Y.,
Wilson, T. A.,
Gautschi, I.,
Shimkets, R.,
Nelson-Williams, C.,
Rossier, B. C.,
and Lifton, R. P.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
11495-11499[Abstract/Free Full Text]
|
| 26.
|
Tamura, H.,
Schild, L.,
Enomoto, N.,
Matsui, N.,
Marumo, F.,
Rossier, B. C.,
and Sasaki, S.
(1996)
J. Clin. Invest.
97,
1780-1784[Medline]
[Order article via Infotrieve]
|
| 27.
|
Melander, O.,
Orho, M.,
Fagerudd, J.,
Bengtsson, K.,
Groop, P.,
Mattiasson, I.,
Groop, L.,
and Hulthen, U. L.
(1998)
Hypertension
31,
1118-1124[Abstract/Free Full Text]
|
| 28.
|
Jeunemaitre, X.,
Bassilana, F.,
Persu, A.,
Dumont, C.,
Champigny, G.,
Lazdunski, M.,
Corvol, P.,
and Barbry, P.
(1997)
J. Hypertension
15,
1091-1100[CrossRef][Medline]
[Order article via Infotrieve]
|
| 29.
|
Inoue, J.,
Iwaoka, T.,
Tokunaga, H.,
Takamune, K.,
Naomi, S.,
Araki, M.,
Takahama, K.,
Yamaguchi, K.,
and Tomita, K.
(1998)
J. Clin. Endocrinol. Metab.
83,
2210-2213[Abstract/Free Full Text]
|
| 30.
|
Sudol, M.
(1996)
Prog. Biophys. Mol. Biol.
65,
113-132[Medline]
[Order article via Infotrieve]
|
| 31.
|
Staub, O.,
Dho, S.,
Henry, P. C.,
Correa, J.,
Ishikawa, T.,
McGlade, J.,
and Rotin, D.
(1996)
EMBO J.
15,
2371-2380[Medline]
[Order article via Infotrieve]
|
| 32.
|
Goulet, C. C.,
Volk, K. A.,
Adams, C. M.,
Prince, L. S.,
Stokes, J. B.,
and Snyder, P. M.
(1998)
J. Biol. Chem.
273,
30012-30017[Abstract/Free Full Text]
|
| 33.
|
Abriel, H.,
Loffing, J.,
Rebhun, J. F.,
Pratt, J. H.,
Schild, L.,
Horisberger, J.,
Rotin, D.,
and Staub, O.
(1999)
J. Clin. Invest.
103,
667-673[Medline]
[Order article via Infotrieve]
|
| 34.
|
Harvey, K. F.,
Dinudom, A.,
Komwatana, P.,
Jolliffe, C. N.,
Day, M. L.,
Parasivam, G.,
Cook, D. I.,
and Kumar, S.
(1999)
J. Biol. Chem.
274,
12525-12530[Abstract/Free Full Text]
|
| 35.
|
Firsov, D.,
Schild, L.,
Gautschi, I.,
Merillat, A.,
Schneeberger, E.,
and Rossier, B. C.
(1996)
Proc. Natl. Acad. Sci.
93,
15370-15375[Abstract/Free Full Text]
|
| 36.
|
Schild, L.,
Lu, Y.,
Gautschi, I.,
Schneeberger, E.,
Lifton, R. P.,
and Rossier, B. C.
(1996)
EMBO J.
15,
2381-2387[Medline]
[Order article via Infotrieve]
|
| 37.
|
Volk, K. A.,
Husted, R. F.,
Snyder, P. M.,
and Stokes, J. B.
(2000)
Am. J. Physiol. Cell Physiol.
278,
C1047-C1054[Abstract/Free Full Text]
|
| 38.
|
Chen, S.,
Bhargava, A.,
Mastroberardino, L.,
Meijer, O. C.,
Wang, J.,
Buse, P.,
Firestone, G. L.,
Verrey, F.,
and Pearce, D.
(1999)
Proc. Natl. Acad. Sci.
96,
2514-2519[Abstract/Free Full Text]
|
| 39.
|
Naray-Fejes-Toth, A.,
Canessa, C.,
Cleaveland, E. S.,
Aldrich, G.,
and Fejes-Toth, G.
(1999)
J. Biol. Chem.
274,
16973-16978[Abstract/Free Full Text]
|
| 40.
|
Kobayashi, T.,
Deak, M.,
Morrice, N.,
and Cohen, P.
(1999)
Biochem. J.
344,
189-197
|
| 41.
|
Park, J.,
Leong, M. L. L.,
Buse, P.,
Maiyar, A. C.,
Firestone, G. L.,
and Hemmings, B. A.
(1999)
EMBO J.
18,
3024-3033[CrossRef][Medline]
[Order article via Infotrieve]
|
| 42.
|
Snyder, P. M.,
Bucher, D. B.,
and Olson, D. R.
(2000)
J. Gen. Physiol.
116,
781-790[Abstract/Free Full Text]
|
| 43.
|
Alverez de la Rosa, D.,
Zhang, P.,
Naray-Fejes-Toth, A.,
Fejes-Toth, G.,
and Canessa, C. M.
(1999)
J. Biol. Chem.
274,
37834-37839[Abstract/Free Full Text]
|
| 44.
|
Lang, F.,
Klingel, K.,
Wagner, C. A.,
Stegen, C.,
Warntges, S.,
Friedrich, B.,
Lanzendorfer, M.,
Meizig, J.,
Moschen, I.,
Steuer, S.,
Waldegger, S.,
Sauter, M.,
Paulmichl, M.,
Gerke, V.,
Risler, T.,
Gamba, G.,
Capasso, G.,
Kandolf, R.,
Hebert, S. C.,
Massry, S. G.,
and Broer, S.
(2000)
Proc. Natl. Acad. Sci.
97,
8157-8162[Abstract/Free Full Text]
|
| 45.
|
Shimkets, R. A.,
Lifton, R.,
and Canessa, C. M.
(1998)
Proc. Natl. Acad. Sci.
95,
3301-3305[Abstract/Free Full Text]
|
| 46.
|
Chigaev, A.,
Lu, G.,
Shi, H.,
Asher, C.,
Xu, R.,
Latter, H.,
Seger, R.,
Garty, H.,
and Reuveny, E.
(2001)
Am. J. Physiol.
280,
F1030-F1036
|
| 47.
|
Copeland, S. J.,
Berdiev, B. K.,
Ji, H. L.,
Lockhart, J.,
Parker, S.,
Fuller, C. M.,
and Benos, D. J.
(2001)
Am. J. Physiol.
281,
C231-C240[Abstract/Free Full Text]
|
| 48.
|
Qi, J.,
Peters, K. W.,
Liu, C.,
Wang, J.,
Edinger, R. S.,
Johnson, J. P.,
Watkins, S. C.,
and Frizzell, R. A.
(1999)
J. Biol. Chem.
274,
30345-30348[Abstract/Free Full Text]
|
| 49.
|
Saxena, S.,
Quick, M. W.,
Tousson, A.,
Oh, Y.,
and Warnock, D. G.
(1999)
J. Biol. Chem.
274,
20812-20817[Abstract/Free Full Text]
|
Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
G. M. Mueller, O. B. Kashlan, J. B. Bruns, A. B. Maarouf, M. Aridor, T. R. Kleyman, and R. P. Hughey
Epithelial Sodium Channel Exit from the Endoplasmic Reticulum Is Regulated by a Signal within the Carboxyl Cytoplasmic Domain of the {alpha} Subunit
J. Biol. Chem.,
November 16, 2007;
282(46):
33475 - 33483.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. F. Husted, K. A. Volk, R. D. Sigmund, and J. B. Stokes
Discordant effects of corticosteroids and expression of subunits on ENaC activity
Am J Physiol Renal Physiol,
September 1, 2007;
293(3):
F813 - F820.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. M. Snyder
Minireview: Regulation of Epithelial Na+ Channel Trafficking
Endocrinology,
December 1, 2005;
146(12):
5079 - 5085.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. K. Berdiev, B. Jovov, W. C. Tucker, A. P. Naren, C. M. Fuller, E. R. Chapman, and D. J. Benos
ENaC subunit-subunit interactions and inhibition by syntaxin 1A
Am J Physiol Renal Physiol,
June 1, 2004;
286(6):
F1100 - F1106.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. E. Booth, Q. Tong, J. Medina, P. M. Snyder, P. Patel, and J. D. Stockand
A Region Directly Following the Second Transmembrane Domain in {gamma}ENaC Is Required for Normal Channel Gating
J. Biol. Chem.,
October 17, 2003;
278(42):
41367 - 41379.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. S. Leonard, O. Yermolaieva, A. Hruska-Hageman, C. C. Askwith, M. P. Price, J. A. Wemmie, and M. J. Welsh
cAMP-dependent protein kinase phosphorylation of the acid-sensing ion channel-1 regulates its binding to the protein interacting with C-kinase-1
PNAS,
February 18, 2003;
100(4):
2029 - 2034.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Becchetti, B. Malik, G. Yue, P. Duchatelle, O. Al-Khalili, T. R. Kleyman, and D. C. Eaton
Phosphatase inhibitors increase the open probability of ENaC in A6 cells
Am J Physiol Renal Physiol,
November 1, 2002;
283(5):
F1030 - F1045.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2001 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|